Home › Companies › ARS Pharmaceuticals, Inc. › 2025-2026

ARS Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and ARS Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-25 (Item 5.07 on EDGAR). Page generated 02 October 2026.

7Reported items
237Asset managers
1,391Fund votes
2026-06-24Meeting date

Proxy season: 2025-2026

Explore ARS Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by ARS Pharmaceuticals, Inc.

These tallies are ARS Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-25 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ARS Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2026-06-24
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Saqib Islam, J.D.	51,588,419	--	--	14,429,366	14,111,827	Majority: yes
Elect Director: Phillip Schneider	38,474,013	--	--	27,543,772	14,111,827	Majority: yes
Elect Director: Laura Shawver, Ph.D.	45,149,811	--	--	20,867,974	14,111,827	Majority: yes
Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered	79,465,541	102,436	561,635	--	--	Majority: yes
Proposal 3: Advisory Vote on the Compensation of the Company's Named Executive Officers	57,290,450	8,104,466	622,869	--	14,111,827	Majority: yes

Source: ARS Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-25 — read the filing on EDGAR.

How asset managers voted at the ARS Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 237 asset managers that disclosed a ARS Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ARS Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 10 wordings of this item as funds reported it.

88% Majority: yes · of votes cast

FOR 88%12%

FOR: 57,290,450AGAINST: 8,104,466

ARS Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Advisory Vote on the Compensation of the Company's Named Executive Officers”): 57,290,450 for, 8,104,466 against, per its Form 8-K filed 2026-06-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,300,137 outstanding shares: 58% for, 8% against (66% of the company cast a for/against vote).

The 236 asset managers below cast 80% of the shares they voted on this item FOR (40,535,080 for, 9,924,674 against).

FOR 80%AGAINST 20%

FOR: 40,535,080 (80.3%)AGAINST: 9,924,674 (19.7%)ABSTAIN: 1,232 (0.0%)NOT VOTED: 319 (0.0%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at ARS Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
RA CAPITAL MANAGEMENT, L.P.	10,860,977	0	0	For
ORBIMED ADVISORS LLC	8,288,510	0	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	6,612,986	0	0	For
Aberdeen	0	5,889,478	0	Against
SR ONE CAPITAL MANAGEMENT, LP	4,012,903	0	0	For
Janney Montgomery Scott LLC	2,021,635	0	0	For
BAMCO INC /NY/	1,074,609	0	0	For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	1,074,609	0	0	For
ADAR1 Capital Management, LLC	0	1,060,579	0	Against
BlackRock	982,004	52,968	1,232	For
GENERAL AMERICAN INVESTORS CO INC	931,266	0	0	For
State Street	729,899	4,835	0	For
Tyro Capital Management LLC	716,960	0	0	For
Allspring	0	592,720	0	Against
Fidelity	96,550	473,052	0	Against
LEVIN CAPITAL STRATEGIES, L.P.	323,001	0	0	For
Northern Trust	0	276,279	0	Against
OPTIMUM FUND TRUST	228,121	0	0	For
PEREGRINE CAPITAL MANAGEMENT LLC	224,464	0	0	For
FRANKLIN ADVISERS INC	0	213,378	0	Against
BARON CAPITAL MANAGEMENT INC /NY/	198,732	0	0	For
Vanguard	183,782	516	0	For
FRANKLIN STRATEGIC SERIES	0	170,375	0	Against
Goldman Sachs	165,921	0	0	For
DAFNA Capital Management LLC	139,285	0	0	For

Showing the 25 largest of 236 asset managers. See all 236 in the interactive database.

2. To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

85% fund support · no official result

ONE YEAR 56%1 YEAR 44%

The 225 asset managers below cast 85% of the shares they voted on this item FOR (60,161 for, 10,261 against).

FOR: 60,161 (0.1%)AGAINST: 10,261 (0.0%)ONE YEAR: 23,630,460 (55.8%)1 YEAR: 18,658,681 (44.0%)THREE YEARS: 10,579 (0.0%)1-YEAR: 788 (0.0%)NOT VOTED: 319 (0.0%)3 YEARS: 164 (0.0%)1.0: 9 (0.0%)

Largest asset managers voting on “To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation o” at ARS Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
ORBIMED ADVISORS LLC	0	0	0	0	1 Year
RA CAPITAL MANAGEMENT, L.P.	0	0	0	0	One Year
DEERFIELD MANAGEMENT COMPANY, L.P.	0	0	0	0	1 Year
Aberdeen	0	0	0	0	One Year
Janney Montgomery Scott LLC	0	0	0	0	One Year
BAMCO INC /NY/	0	0	0	0	One Year
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	0	0	0	0	One Year
ADAR1 Capital Management, LLC	0	0	0	0	One Year
BlackRock	0	0	0	0	1 Year
GENERAL AMERICAN INVESTORS CO INC	0	0	0	0	1 Year
State Street	0	0	0	0	One Year
Allspring	0	0	0	0	One Year
Fidelity	0	0	0	0	One Year
LEVIN CAPITAL STRATEGIES, L.P.	0	0	0	0	1 Year
Northern Trust	0	0	0	0	1 Year
OPTIMUM FUND TRUST	0	0	0	0	One Year
PEREGRINE CAPITAL MANAGEMENT LLC	0	0	0	0	One Year
FRANKLIN ADVISERS INC	0	0	0	0	One Year
BARON CAPITAL MANAGEMENT INC /NY/	0	0	0	0	One Year
Vanguard	0	0	0	0	One Year
FRANKLIN STRATEGIC SERIES	0	0	0	0	One Year
Goldman Sachs	0	0	0	0	One Year
DAFNA Capital Management LLC	0	0	0	0	1 Year
BANK OF AMERICA NA	0	0	0	0	1 Year
Advisors' Inner Circle Fund III	0	0	0	0	1 Year

Showing the 25 largest of 225 asset managers. See all 225 in the interactive database.

3. To elect our Board of Directors' three nominees for Class III director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Laura Shawver, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

68% Majority: yes · of votes cast

FOR 68%WITHHELD 32%

FOR: 45,149,811WITHHELD: 20,867,974

ARS Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Laura Shawver, Ph.D.”): 45,149,811 for, 20,867,974 withheld, per its Form 8-K filed 2026-06-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,300,137 outstanding shares: 45.5% for, 21% withheld (66% of the company cast a for/withheld vote).

The 53 asset managers below cast 100% of the shares they voted on this item FOR (4,772,054 for, 0 against).

FOR 79%ABSTAIN 21%

FOR: 4,772,054 (78.9%)ABSTAIN: 1,274,281 (21.1%)

Largest asset managers voting on “To elect our Board of Directors' three nominees for Class III director named in the accompanying proxy stateme” at ARS Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Aberdeen	1,783,628	0	For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	1,074,609	0	For
GENERAL AMERICAN INVESTORS CO INC	931,266	0	For
BlackRock	0	308,898	Abstain
Allspring	0	296,360	Abstain
State Street	257,254	375	For
OPTIMUM FUND TRUST	228,121	0	For
FRANKLIN STRATEGIC SERIES	0	170,375	Abstain
Vanguard	152,856	159	For
Advisors' Inner Circle Fund III	117,835	0	For
Empower	95,250	0	For
Fidelity	17,477	58,473	Abstain
SIT MUTUAL FUNDS INC	0	73,100	Abstain
Lincoln Financial	70,016	0	For
Royce	0	54,000	Abstain
Charles Schwab	0	52,570	Abstain
Equitable	0	52,339	Abstain
QUANTITATIVE MASTER SERIES LLC	0	51,206	Abstain
Direxion Shares ETF Trust	0	33,752	Abstain
JPMorgan	27,568	0	For
ALPS ETF Trust	0	19,543	Abstain
Brighthouse	0	13,031	Abstain
Bridge Builder Trust	0	11,375	Abstain
American Century	0	8,875	Abstain
DWS	0	8,461	Abstain

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

4. To elect our Board of Directors' three nominees for Class III director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Phillip Schneider

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

58% Majority: yes · of votes cast

FOR 58%WITHHELD 42%

FOR: 38,474,013WITHHELD: 27,543,772

ARS Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Phillip Schneider”): 38,474,013 for, 27,543,772 withheld, per its Form 8-K filed 2026-06-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,300,137 outstanding shares: 39% for, 28% withheld (66% of the company cast a for/withheld vote).

The 53 asset managers below cast 100% of the shares they voted on this item FOR (1,577,680 for, 0 against).

FOR 26%ABSTAIN 74%

FOR: 1,577,680 (26.1%)ABSTAIN: 4,468,655 (73.9%)

Largest asset managers voting on “To elect our Board of Directors' three nominees for Class III director named in the accompanying proxy stateme” at ARS Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Aberdeen	0	1,783,628	Abstain
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	0	1,074,609	Abstain
GENERAL AMERICAN INVESTORS CO INC	931,266	0	For
BlackRock	0	308,898	Abstain
Allspring	0	296,360	Abstain
State Street	186	257,443	Abstain
OPTIMUM FUND TRUST	228,121	0	For
FRANKLIN STRATEGIC SERIES	0	170,375	Abstain
Vanguard	152,547	468	For
Advisors' Inner Circle Fund III	0	117,835	Abstain
Empower	95,250	0	For
Fidelity	51,033	24,917	For
SIT MUTUAL FUNDS INC	0	73,100	Abstain
Lincoln Financial	29,816	40,200	Abstain
Royce	0	54,000	Abstain
Charles Schwab	52,570	0	For
Equitable	0	52,339	Abstain
QUANTITATIVE MASTER SERIES LLC	0	51,206	Abstain
Direxion Shares ETF Trust	0	33,752	Abstain
JPMorgan	27,568	0	For
ALPS ETF Trust	0	19,543	Abstain
Brighthouse	0	13,031	Abstain
Bridge Builder Trust	0	11,375	Abstain
American Century	0	8,875	Abstain
DWS	0	8,461	Abstain

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

5. To elect our Board of Directors' three nominees for Class III director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Saqib Islam, J.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD 22%

FOR: 51,588,419WITHHELD: 14,429,366

ARS Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Saqib Islam, J.D.”): 51,588,419 for, 14,429,366 withheld, per its Form 8-K filed 2026-06-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,300,137 outstanding shares: 52.0% for, 15% withheld (66% of the company cast a for/withheld vote).

The 53 asset managers below cast 100% of the shares they voted on this item FOR (5,893,471 for, 0 against).

FOR 97%

FOR: 5,893,471 (97.5%)ABSTAIN: 152,863 (2.5%)

Largest asset managers voting on “To elect our Board of Directors' three nominees for Class III director named in the accompanying proxy stateme” at ARS Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Aberdeen	1,783,628	0	For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	1,074,609	0	For
GENERAL AMERICAN INVESTORS CO INC	931,266	0	For
BlackRock	308,898	0	For
Allspring	296,360	0	For
State Street	257,297	332	For
OPTIMUM FUND TRUST	228,121	0	For
FRANKLIN STRATEGIC SERIES	170,375	0	For
Vanguard	152,707	308	For
Advisors' Inner Circle Fund III	0	117,835	Abstain
Empower	95,250	0	For
Fidelity	75,950	0	For
SIT MUTUAL FUNDS INC	73,100	0	For
Lincoln Financial	70,016	0	For
Royce	54,000	0	For
Charles Schwab	52,570	0	For
Equitable	19,369	32,970	Abstain
QUANTITATIVE MASTER SERIES LLC	51,206	0	For
Direxion Shares ETF Trust	33,752	0	For
JPMorgan	27,568	0	For
ALPS ETF Trust	19,543	0	For
Brighthouse	13,031	0	For
Bridge Builder Trust	11,375	0	For
American Century	8,875	0	For
DWS	8,461	0	For

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

6. TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 79,465,541AGAINST: 102,436

ARS Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP”): 79,465,541 for, 102,436 against, per its Form 8-K filed 2026-06-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 99,300,137 outstanding shares: 80% for, 0.2% against (80% of the company cast a for/against vote).

The 53 asset managers below cast 100% of the shares they voted on this item FOR (6,046,334 for, 0 against).

FOR 100%

FOR: 6,046,334 (100.0%)

Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDE” at ARS Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Vote
Aberdeen	1,783,628	For
BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	1,074,609	For
GENERAL AMERICAN INVESTORS CO INC	931,266	For
BlackRock	308,898	For
Allspring	296,360	For
State Street	257,629	For
OPTIMUM FUND TRUST	228,121	For
FRANKLIN STRATEGIC SERIES	170,375	For
Vanguard	153,015	For
Advisors' Inner Circle Fund III	117,835	For
Empower	95,250	For
Fidelity	75,950	For
SIT MUTUAL FUNDS INC	73,100	For
Lincoln Financial	70,016	For
Royce	54,000	For
Charles Schwab	52,570	For
Equitable	52,339	For
QUANTITATIVE MASTER SERIES LLC	51,206	For
Direxion Shares ETF Trust	33,752	For
JPMorgan	27,568	For
ALPS ETF Trust	19,543	For
Brighthouse	13,031	For
Bridge Builder Trust	11,375	For
American Century	8,875	For
DWS	8,461	For

Showing the 25 largest of 53 asset managers. See all 53 in the interactive database.

7. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

ONE YEAR 97%

The 6 asset managers below cast 100% of the shares they voted on this item FOR (6,623 for, 0 against).

FOR: 6,623 (0.2%)ONE YEAR: 3,124,584 (97.1%)1 YEAR: 85,614 (2.7%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at ARS Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Vote
RA CAPITAL MANAGEMENT, L.P.	0	One Year
Eversept Partners, LP	0	One Year
Local Pensions Partnership Investment Ltd	0	1 Year
WEXFORD CAPITAL LP	0	One Year
FORUM FUNDS II	6,623	For
TD Waterhouse Canada Inc.	0	One Year

Largest ARS Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked by the number of ARS Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 99,300,137 shares outstanding at the time of that meeting.

Top ARS Pharmaceuticals, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	RA CAPITAL MANAGEMENT, L.P.	10.94%
2	ORBIMED ADVISORS LLC	8.35%
3	DEERFIELD MANAGEMENT COMPANY, L.P.	6.66%
4	Aberdeen	5.93%
5	SR ONE CAPITAL MANAGEMENT, LP	4.04%
6	Janney Montgomery Scott LLC	2.04%
7	BAMCO INC /NY/	1.08%
8	BARON INVESTMENT FUNDS TRUST (f/k/a BARON ASSET FUND)	1.08%
9	ADAR1 Capital Management, LLC	1.07%
10	BlackRock	1.04%

Reported ARS Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ARS Pharmaceuticals, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Richard Lowenthal, M.S., MSEL	12.17%	DEF14A
Peter Kolchinsky, Ph.D.	11.02%	DEF14A
Entities affiliated with RA Capital	10.94%	DEF14A
Entities affiliated with OrbiMed	8.35%	DEF14A
Entities affiliated with Deerfield Management Company, L.P.	7.66%	DEF14A
Entities affiliated with Rubric Capital Management LP	6.24%	DEF14A
Millennium Management	6.03%	13F
Entities affiliated with Millennium Management LLC	5.96%	DEF14A
Entities affiliated with BlackRock, Inc.	5.05%	DEF14A
BlackRock	5.05%	13F

Percentages above are of 99,300,137 shares outstanding, as reported by ARS Pharmaceuticals, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARS Pharmaceuticals, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At ARS Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-24, in the 2025-2026 proxy season, 237 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,391 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 88% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ARS Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-25.

ARS Pharmaceuticals, Inc. proxy season coverage: 2025-2026 (this page).